The Forces Behind Cell Movement

por Ananthakrishnan, Revathi, Ehrlicher, Allen
Publicado 2007

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials

por Ananthakrishnan, Revathi, Green, Stephanie, Li, Daniel, LaValley, Michael
Publicado 2018

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy

por Ananthakrishnan, Revathi, Green, Stephanie, Li, Daniel, LaValley, Michael
Publicado 2019

Systematic comparison of the statistical operating characteristics of various Phase I oncology designs

por Ananthakrishnan, Revathi, Green, Stephanie, Chang, Mark, Doros, Gheorghe, Massaro, Joseph, LaValley, Michael
Publicado 2016

An overview of the BOIN design and its current extensions for novel early-phase oncology trials

por Ananthakrishnan, Revathi, Lin, Ruitao, He, Chunsheng, Chen, Yanping, Li, Daniel, LaValley, Michael
Publicado 2022

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

por Minakata, Daisuke, Ishida, Tadao, Ando, Kiyoshi, Suzuki, Rikio, Tanaka, Junji, Hagiwara, Shotaro, Ananthakrishnan, Revathi, Kuwayama, Shigeki, Nishio, Mitsufumi, Kanda, Yoshinobu, Suzuki, Kenshi
Publicado 2023

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

por Sangha, Randeep, Davies, Andrew, Dang, Nam H., Ogura, Michinori, MacDonald, David A., Ananthakrishnan, Revathi, Paccagnella, M. Luisa, Vandendries, Erik, Boni, Joseph, Goh, Yeow Tee
Publicado 2017

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

por Makita, Shinichi, Yamamoto, Go, Maruyama, Dai, Asano‐Mori, Yuki, Kaji, Daisuke, Ananthakrishnan, Revathi, Ogasawara, Ken, Stepan, Lara, Schusterbauer, Claudia, Rettby, Nils, Hasskarl, Jens, Izutsu, Koji
Publicado 2022